FindTrial
Sign In

Atezolizumab Injection

DRUG5 trials

Sponsors

National Taiwan University Hospital, Gustave Roussy, Cancer Campus, Grand Paris, Federation Francophone de Cancerologie Digestive, Yale University, Nanjing Leads Biolabs Co.,Ltd

Conditions

Advanced Neuroendocrine CarcinomaBCLC Stage B Hepatocellular CarcinomaBreast CancerEsophageal CancerHCC - Hepatocellular CarcinomaHepatocellular CarcinomaMetastatic CancerMetastatic Tumor

Phase 1

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
RecruitingNCT06157827
Nanjing Leads Biolabs Co.,LtdAdvanced Neuroendocrine Carcinoma
Start: 2023-12-08End: 2027-03-28Target: 178Updated: 2026-03-12

Phase 2

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
CompletedNCT05007613
National Taiwan University HospitalEsophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma
Start: 2021-06-23End: 2024-12-01Updated: 2025-01-01
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
TerminatedNCT05180006
Gustave Roussy, Cancer Campus, Grand ParisBreast Cancer
Start: 2022-02-24End: 2024-12-17Updated: 2025-12-01
Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
CompletedNCT05665348
Federation Francophone de Cancerologie DigestiveHCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
Start: 2023-03-09End: 2025-05-12Updated: 2026-03-09
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
TerminatedNCT05776875
Yale UniversityBCLC Stage B Hepatocellular Carcinoma, Hepatocellular Carcinoma
Start: 2023-06-07End: 2024-12-05Updated: 2025-01-15

Related Papers

Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial.
Journal of Clinical Oncology2025-05-28
Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2024-06-011 citations
Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.
Journal of Clinical Oncology2024-06-01
Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
Journal of Clinical Oncology2024-01-20
156TiP Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)
ESMO Open2023-05-012 citations
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial.
2023-02-1618 citations
A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy.
Journal of Clinical Oncology2022-01-19